{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T21:34:01Z","timestamp":1777584841688,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.mehy.2019.109546","type":"journal-article","created":{"date-parts":[[2020,1,2]],"date-time":"2020-01-02T11:36:25Z","timestamp":1577964985000},"page":"109546","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Low-Dose Naltrexone reduces symptoms in Stiff-Person Syndrome"],"prefix":"10.1016","volume":"137","author":[{"given":"Mauro","family":"Zappaterra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Shouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reed Loring","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.mehy.2019.109546_b0005","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/mus.23234","article-title":"Autoimmune stiff person syndrome and related myelopathies: understanding of electrophysiological and immunological processes","volume":"45","author":"Rakocevic","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.mehy.2019.109546_b0010","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1212\/01.WNL.0000163984.71993.FE","article-title":"A neuropsychological assessment of phobias in patients with stiff person syndrome","volume":"65","author":"Ameli","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.mehy.2019.109546_b0015","unstructured":"What is Stiff Person Syndrome? National Institute of Neurological Disorders and Stroke Web site. http:\/\/www.ninds.nih.gov\/disorders\/stiffperson\/stiffperson.htm Published November 15, 2010. Accessed February 8, 2014."},{"issue":"1","key":"10.1016\/j.mehy.2019.109546_b0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00415-005-1105-4","article-title":"The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies","volume":"252","author":"Dalakas","year":"2005","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.mehy.2019.109546_b0025","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1124\/jpet.106.118810","article-title":"Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist treatment","volume":"321","author":"Wang","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.mehy.2019.109546_b0030","first-page":"321","article-title":"Antagonists, Inverse Agonists, and Protagonists","volume":"23","author":"Shader","year":"2003","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.mehy.2019.109546_b0035","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bbi.2006.10.011","article-title":"Norman cousins lecture. Glia as the \u201cbad guys\u201d: implications for improving clinical pain control and the clinical utility of opioids","volume":"21","author":"Watkins","year":"2007","journal-title":"Brain Behav Immun"},{"issue":"4","key":"10.1016\/j.mehy.2019.109546_b0040","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10067-014-2517-2","article-title":"The use of low-dose naltrexone as a novel anti-inflammatory treatment for chronic pain","volume":"33","author":"Younger","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.mehy.2019.109546_b0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bbi.2006.09.006","article-title":"Twenty years of research on cytokine-induced sickness behavior","volume":"21","author":"Dantzer","year":"2007","journal-title":"Brain Behav Immun"},{"issue":"1","key":"10.1016\/j.mehy.2019.109546_b0050","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/BF02431530","article-title":"\u201cParadoxical\u201d analgesia induced by naloxone and naltrexone","volume":"96","author":"Greeley","year":"1988","journal-title":"Psychopharm [Berlin]"},{"key":"10.1016\/j.mehy.2019.109546_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1572-0241.2007.01045.x","article-title":"Low-Dose naltrexone therapy improves active Crohn\u2019s disease","volume":"102","author":"Smith","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.mehy.2019.109546_b0060","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1007\/s10620-011-1653-7","article-title":"Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn\u2019s disease: a randomized placebo-controlled trial","volume":"56","author":"Smith","year":"2011","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.mehy.2019.109546_b0065","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/MCG.0b013e3182702f2b","article-title":"Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn\u2019s disease: a pilot study","volume":"47","author":"Smith","year":"2013","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.mehy.2019.109546_b0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2174\/1568026043451519","article-title":"Expression of opioid receptors during peripheral inflammation","volume":"4","author":"Pol","year":"2004","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.mehy.2019.109546_b0075","article-title":"Opioid G Protein-coupled receptors: signals at the crossroads of inflammation","author":"Rogers","year":"200324","journal-title":"Trends Immunol"},{"key":"10.1016\/j.mehy.2019.109546_b0080","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0165-5728(97)00240-3","article-title":"Role of endogenous pro-enkephalin A-derived peptides in human T cell proliferation and monocyte IL-6 production","volume":"84","author":"Kamphuis","year":"1998","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.mehy.2019.109546_b0085","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1177\/1352458508095828","article-title":"A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis","volume":"14","author":"Gironi","year":"2008","journal-title":"Mult Scler"},{"key":"10.1016\/j.mehy.2019.109546_b0090","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ana.22006","article-title":"Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis","volume":"68","author":"Cree","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.mehy.2019.109546_b0095","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.mehy.2004.09.024","article-title":"Low dose naltrexone therapy in multiple sclerosis","volume":"64","author":"Agrawal","year":"2005","journal-title":"Med Hypotheses"},{"issue":"4","key":"10.1016\/j.mehy.2019.109546_b0100","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/j.1526-4637.2009.00613.x","article-title":"Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study","volume":"10","author":"Younger","year":"2009","journal-title":"Pain Med"},{"issue":"6","key":"10.1016\/j.mehy.2019.109546_b0105","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.psym.2011.11.006","article-title":"Is Fibromylagia an endocrine\/endorphin deficit disorder? Is low dose naltrexone a new treatment option?","volume":"53","author":"Ramanathan","year":"2012","journal-title":"Psychosomatics"},{"key":"10.1016\/j.mehy.2019.109546_b0110","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.mehy.2008.06.048","article-title":"Low-dose naltrexone for disease prevention and quality of life","volume":"72","author":"Brown","year":"2009","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.mehy.2019.109546_b0115","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jpain.2005.01.356","article-title":"Adding ultra-low-dose naltrexone to oxycodone enhances and prolongs analgesia","volume":"6","author":"Chindalore","year":"2005","journal-title":"J Pain"},{"issue":"3","key":"10.1016\/j.mehy.2019.109546_b0120","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s11481-013-9451-y","article-title":"Treatment of complex regional pain syndrome [CRPS] using low dose naltrexone [LDN]","volume":"8","author":"Chopra","year":"2013","journal-title":"J Neuroimmune Pharm"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987719312514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987719312514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:19:23Z","timestamp":1759691963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987719312514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":24,"alternative-id":["S0306987719312514"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2019.109546","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-Dose Naltrexone reduces symptoms in Stiff-Person Syndrome","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2019.109546","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109546"}}